|
US6402215B1
(en)
*
|
1996-05-21 |
2002-06-11 |
American Moto Products, Inc. |
Vehicle cargo bed extender
|
|
EP2392565B1
(en)
|
2003-09-26 |
2014-03-19 |
Exelixis, Inc. |
c-Met modulators and methods of use
|
|
JP5368701B2
(ja)
|
2004-07-02 |
2013-12-18 |
エクセリクシス、インコーポレイテッド |
ｃ−Ｍｅｔモジュレーター及び使用方法
|
|
CA2603748A1
(en)
|
2005-04-06 |
2006-10-12 |
Exelixis, Inc. |
C-met modulators and methods of use
|
|
JP5311673B2
(ja)
|
2006-12-14 |
2013-10-09 |
エグゼリクシス， インコーポレイテッド |
Ｍｅｋ阻害剤の使用方法
|
|
UY31800A
(es)
|
2008-05-05 |
2009-11-10 |
Smithkline Beckman Corp |
Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb
|
|
AR075084A1
(es)
|
2008-09-26 |
2011-03-09 |
Smithkline Beecham Corp |
Metodo de preparacion de quinolinil -oxidifenil - ciclopropanodicarboxamidas e intermediarios correspondientes
|
|
CN102282134B
(zh)
|
2008-11-13 |
2015-04-01 |
埃克塞里艾克西斯公司 |
喹啉衍生物制备方法
|
|
WO2010065838A1
(en)
|
2008-12-04 |
2010-06-10 |
Exelixis, Inc. |
Methods of preparing quinoline derivatives
|
|
RS52754B2
(sr)
|
2009-01-16 |
2022-08-31 |
Exelixis Inc |
Malat so n-(4- {[6,7-bis(metiloksi)hinolin-4-il]oksi}fenil-n'- (4-fluorofenil) ciklopropan-1,1-dikarboksamid-a, i njeni kristalni oblici za lečenje karcinoma
|
|
EP2454238A1
(en)
|
2009-07-17 |
2012-05-23 |
Exelixis, Inc. |
Crystalline forms of n-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]-quinolin-4-yl}oxy)phenyl]-n'-(4-fluorophenyl)cyclopropane-1, 1-dicarboxamide
|
|
UA108618C2
(uk)
|
2009-08-07 |
2015-05-25 |
|
Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
|
|
EA025304B1
(ru)
*
|
2010-02-03 |
2016-12-30 |
Инсайт Холдингс Корпорейшн |
ИМИДАЗО[1,2-b][1,2,4]ТРИАЗИНЫ В КАЧЕСТВЕ c-Met ИНГИБИТОРОВ
|
|
CN102933551A
(zh)
|
2010-03-12 |
2013-02-13 |
埃克塞里艾克西斯公司 |
N-[3-氟-4-({6-(甲氧基)-7-[(3-吗啉-4-基丙基)氧基]-喹啉-4-基}氧基)苯基]-n’-(4-氟苯基)环丙烷-1,1-二甲酰胺的水合结晶形式
|
|
US20120070368A1
(en)
|
2010-04-16 |
2012-03-22 |
Exelixis, Inc. |
Methods of Using C-Met Modulators
|
|
EP2593091A1
(en)
|
2010-07-16 |
2013-05-22 |
Exelixis, Inc. |
C-met modulator pharmaceutical compositions
|
|
KR20180056807A
(ko)
|
2010-07-16 |
2018-05-29 |
엑셀리시스, 인코포레이티드 |
C-met 조절제 약제학적 조성물
|
|
PL2621481T5
(pl)
|
2010-09-27 |
2023-03-13 |
Exelixis, Inc. |
Podwójne inhibitory MET i VEGF do leczenia opornego na kastrację raka prostaty i osteoblastycznych przerzutów do kości
|
|
JP2013537918A
(ja)
|
2010-09-27 |
2013-10-07 |
エクセリクシス， インク． |
去勢抵抗性前立腺癌および骨芽細胞骨転移の治療のためのｍｅｔおよびｖｅｇｆの二元阻害薬
|
|
WO2012044574A1
(en)
|
2010-09-27 |
2012-04-05 |
Exelixis, Inc. |
Dual inhibitors of met and vegf for the treatment of castration resistant prostate cancer and osteoblastic bone metastases
|
|
WO2012064967A2
(en)
*
|
2010-11-10 |
2012-05-18 |
Cedars-Sinai Medical Center |
Cancer cell-derived receptor activator of the nf-kb ligand drives bone and soft tissue metastases
|
|
JP2013543011A
(ja)
|
2010-11-22 |
2013-11-28 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー２、リミテッド |
癌の治療法
|
|
CA2826751C
(en)
|
2011-02-10 |
2021-05-18 |
Exelixis, Inc. |
Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds
|
|
US20120252840A1
(en)
|
2011-04-04 |
2012-10-04 |
Exelixis, Inc. |
Method of Treating Cancer
|
|
JP2014513129A
(ja)
|
2011-05-02 |
2014-05-29 |
エクセリクシス， インク． |
癌および骨癌疼痛の治療方法
|
|
TW201306842A
(zh)
|
2011-06-15 |
2013-02-16 |
Exelixis Inc |
使用ｐｉ３ｋ／ｍｔｏｒ吡啶並嘧啶酮抑制劑及苯達莫司汀及／或利妥昔單抗治療惡性血液疾病之組合療法
|
|
EP2758057B1
(en)
|
2011-09-22 |
2017-05-31 |
Exelixis, Inc. |
Method for treating osteoporosis
|
|
CN104395284A
(zh)
|
2011-10-20 |
2015-03-04 |
埃克塞里艾克西斯公司 |
制备喹啉衍生物的方法
|
|
KR20140088610A
(ko)
|
2011-11-08 |
2014-07-10 |
엑셀리시스, 인코포레이티드 |
암을 치료하기 위한 met 및 vegf의 이중 저해제
|
|
WO2013119693A1
(en)
*
|
2012-02-06 |
2013-08-15 |
The Regents Of The University Of California |
Emp2 regulates angiogenesis in cancer cells through induction of vegf
|
|
CN103304552B
(zh)
*
|
2012-03-09 |
2016-12-28 |
广东东阳光药业有限公司 |
取代的吡啶化合物及其使用方法和用途
|
|
HK1207587A1
(en)
|
2012-05-02 |
2016-02-05 |
Exelixis, Inc. |
A dual met - vegf modulator for treating osteolytic bone metastases
|
|
WO2014039971A1
(en)
|
2012-09-07 |
2014-03-13 |
Exelixis, Inc. |
Inhibitors of met, vegfr and ret for use in the treatment of lung adenocarcinoma
|
|
US20140221372A1
(en)
|
2013-02-06 |
2014-08-07 |
GlaxoSmithKline Intellectual Property (NO 2.) Limited |
Method of administration and treatment
|
|
GEP20196995B
(en)
|
2013-03-15 |
2019-07-25 |
Inc Exelixis |
Metabolites of n-(4-{[6,7-bis (methyloxy)quinolin-4-yl] oxy}phenyl)-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide
|
|
ES2927651T3
(es)
|
2013-04-04 |
2022-11-10 |
Exelixis Inc |
Forma de dosificación de cabozantinib y uso en el tratamiento del cáncer
|
|
CN108472242A
(zh)
|
2013-04-04 |
2018-08-31 |
埃克塞里艾克西斯公司 |
治疗癌症的药物组合
|
|
EP3738952A1
(en)
|
2014-02-14 |
2020-11-18 |
Exelixis, Inc. |
Crystalline solid forms of n-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use
|
|
WO2015142928A1
(en)
|
2014-03-17 |
2015-09-24 |
Exelixis, Inc. |
Dosing of cabozantinib formulations
|
|
EP3906921A1
(en)
|
2014-04-25 |
2021-11-10 |
Exelixis, Inc. |
Method of treating lung adenocarcinoma
|
|
MA40386A
(fr)
|
2014-07-31 |
2016-02-04 |
Exelixis Inc |
Procédé de préparation de cabozantinib marqué au fluor-18 et d'analogues de celui-ci
|
|
EA034992B1
(ru)
|
2014-08-05 |
2020-04-15 |
Экселиксис, Инк. |
Комбинации лекарственных средств для лечения множественной миеломы
|
|
US20170224670A1
(en)
|
2014-10-14 |
2017-08-10 |
Exelixis, Inc. |
Drug Combination to Treat Melanoma
|